Myt1 Antibody

MYT1, also known as Myelin transcription factor 1, consists of a long 1,121 amino acid isoform that is 122 kDa, and is involved in the development of the central nervous system and the regulation of oligodendrocyte lineage development. Current research is being conducted on the relationship between MYT1 and a variety of diseases and disorders, including multiple sclerosis, papillary thyroid carcinoma, leukomalacia, neuronitis, sporadic breast cancer, skin cancer, pancreatitis, schizophrenia, thyroiditis, and carcinoma. The protein interacts with SIN3B, PIN1, PLK1, HDAC1, and CDK1, and has been linked to pancreatic and breast cancer pathways, as well as G1 to S cell cycle control.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Mouse.

We have publications tested in 1 application: IP.

Showing Publications 1 - 3 of 3.

Publications using NBP1-81021	Applications	Species
Islam MM, Smith DK, Niu W et al. Enhancer Analysis Unveils Genetic Interactions between TLX and SOX2 in Neural Stem Cells and In Vivo Reprogramming. Stem Cell Reports 2015-10-20 [PMID: 26607952] (IP, Mouse)	IP	Mouse
Chandrasekar V, Dreyer JL et al. The Brain-Specific Neural Zinc Finger Transcription Factor 2b (NZF-2b/7ZFMyt1) Suppresses Cocaine Self-Administration in Rats. Front Behav Neurosci 2010-04-01 [PMID: 20407577]
Chandrasekar V, Dreyer JL et al. The brain-specific Neural Zinc Finger transcription factor 2b (NZF-2b/7ZFMyt1) causes suppression of cocaine-induced locomotor activity. Neurobiol Dis 2010-01-01 [PMID: 19786102]

Array NBP1-81021

• Myt1 Antibodies
• Myt1 Proteins